{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:59:21Z","timestamp":1768420761241,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bulcan.2025.01.013","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T20:05:15Z","timestamp":1743365115000},"page":"527-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Les lymphomes de la zone marginale\u00a0: les diff\u00e9rentes entit\u00e9s, leur diagnostic et prise en charge en 2024"],"prefix":"10.1016","volume":"112","author":[{"given":"Lucie","family":"Oberic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Carras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2025.01.013_bib0260","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0265","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0270","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMra2102568","article-title":"Marginal-Zone Lymphomas","author":"Rossi","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.bulcan.2025.01.013_bib0275","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/aol-20-13","article-title":"Present role and future perspective of PET-CT in marginal zone lymphoma","volume":"4","author":"Ceriani","year":"2020","journal-title":"Ann Lymphoma"},{"issue":"2","key":"10.1016\/j.bulcan.2025.01.013_bib0280","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hon.2578","article-title":"FDG PET\/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma","volume":"37","author":"Vaxman","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0285","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2005.08.128","article-title":"Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy","volume":"23","author":"Martinelli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0290","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3\u00a0non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0295","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0300","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2\u00a0trial","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.bulcan.2025.01.013_bib0305","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/bloodadvances.2021006844","article-title":"An international analysis evaluating frontline bendamustine with rituximab in extra-nodal marginal zone lymphoma","volume":"6","author":"Alderuccio","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.bulcan.2025.01.013_bib0310","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2016-06-720599","article-title":"AGMT Investigators. A phase 2\u00a0study of rituximab plus lenalidomide formucosa-associated lymphoid tissue lymphoma","volume":"129","author":"Kiesewetter","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0315","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19\u00a0randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2025.01.013_bib0320","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.beha.2017.10.011","article-title":"Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?","volume":"31","author":"Kalpadakis","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"10.1016\/j.bulcan.2025.01.013_bib0325","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance","volume":"132","author":"Kalpadakis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0330","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.284109","article-title":"Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA\/IELSG36\u00a0phase II study","author":"Iannitto","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0335","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2018.36.15_suppl.7515","volume":"36","author":"Rummel","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0340","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.283918","article-title":"IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma","author":"Stathis","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bulcan.2025.01.013_bib0345","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1097\/HS9.0000000000000699","article-title":"Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial","volume":"6","author":"Herold","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0350","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hon.3163_65","article-title":"Rituximab and Ibrutinib combination is safe and effective in untreated splenic and nodal marginal zone lymphomas: planned subset analysis of the IELSG47\/MALIBU Plase II study","volume":"41","author":"Thieblemont","year":"2023","journal-title":"Hematol Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.bulcan.2025.01.013_bib0355","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1182\/blood-2023-186626","article-title":"Cumulative Incidence, Predictors, and Outcomes of Transformation to Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Patients with Marginal Zone Lymphoma","volume":"142","author":"Bommier","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0360","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1182\/bloodadvances.2023010133","article-title":"Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study","author":"Epperla","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0365","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/hon.2822","article-title":"A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas","author":"Vannata","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0370","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus Bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3\u00a0trial","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0375","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bjh.15454","article-title":"High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO","author":"Avivi","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0380","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0385","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1182\/bloodadvances.2023010298","article-title":"Phase 3\u00a0SELENE study: Ibrutinib plus BR\/R-CHOP in previously treated patients with follicular or marginal zone lymphoma","author":"Nastoupil Lj","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0390","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/bloodadvances.2021006083","article-title":"Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma","author":"Phillips","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0395","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of Zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","author":"Opat","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0400","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.18368","article-title":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","author":"Strati","year":"2022","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.bulcan.2025.01.013_bib0405","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2023-181309","article-title":"Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed\/Refractory Follicular Lymphoma: Results from the Phase 1\/2\u00a0BRUIN Study","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0410","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/10428194.2020.1855344","article-title":"Outcomes of patients with up to 6\u00a0years of followup from a phase 2\u00a0study of idelalisib for relapsed indolent lymphomas","author":"Wagner-Johnston","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0415","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/bloodadvances.2020002910","article-title":"Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma","author":"Panayiotidis","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0420","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3\u00a0trial","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0425","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a Dual PI3Kd\/CK1\u00ab Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0430","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/bloodadvances.2023010648","article-title":"A phase 2\u00a0study of the PI3K inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)","author":"Phillips","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0435","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term Follow-up of Patients with Relapsed or Refractory Non\u2013Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0440","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","article-title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study","author":"De Vos","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0445","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/bloodadvances.2019000844","article-title":"Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models","author":"Tarantelli","year":"2020","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1016\/j.bulcan.2025.01.013_bib0450","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2023-178841","article-title":"Monotherapy with Second-Generation BCL2\u00a0Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed\/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1\u00a0Study","volume":"142","author":"Tedeschi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0455","first-page":"215","article-title":"An open-label phase 2\u00a0trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma","author":"Andorsky","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0460","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0465","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.15843","article-title":"Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2\u00a0trial","author":"Becnel","year":"2019","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.bulcan.2025.01.013_bib0470","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-134363","article-title":"Patients with Relapsed\/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2\u00a0Followed By Maintenance","volume":"136","author":"Coleman","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0475","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.bulcan.2025.01.013_bib0480","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2022-162559","article-title":"Iberdomide (CC-220) monotherapy or in combination with an anti-CD20\u00a0monoclonal antibody as effective therapy in patients with Relapsed\/Refractory Lymphoma: Early Results from a Phase 1\/2\u00a0Study","volume":"140","author":"Thieblemont","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0485","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2\u00a0study","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0490","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell\u2013Engaging Bispecific Antibody, nduces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0495","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hon.3163_82","article-title":"Odronextamab in patients with relapsed\/refractory follicular lymphoma (FL) grade 1-3a: results from a prespecified analysis of the pivotal phase ii study ELM-2","volume":"S2","author":"Novelli","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0500","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hon.3163_83","article-title":"Mosunetuzumab demonstrates durable responses in patients with relapsed\/refractory follicular lymphoma and \u22652\u00a0prior therapies: updated analysis of a pivotal phase ii study","volume":"S2","author":"Sehn","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0505","first-page":"280","article-title":"High complete response rate with tnb-486, a novel cd19xcd3\u00a0t-cell engager, in relapsed\/refractory follicular lymphoma: interim results from an ongoing phase 1\u00a0study","author":"Jacobs","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.bulcan.2025.01.013_bib0255","first-page":"496","article-title":"Three-year follow-up analysis of Axicabtagene-ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","author":"Neelapu","year":"2024","journal-title":"Bood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125000943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125000943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T12:45:22Z","timestamp":1745930722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125000943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0007455125000943"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.01.013","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les lymphomes de la zone marginale\u00a0: les diff\u00e9rentes entit\u00e9s, leur diagnostic et prise en charge en 2024","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}